Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imatinib Teva

EU flag

EC fines J&J and Novartis in pay-for-delay case

Says companies delayed entry of generic painkiller

- PMLiVE

Novartis’ Tasigna tops Glivec in long-term trial

Boost ahead of patent expiry for leukaemia drug

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

- PMLiVE

Teva expects big things from improved drug programme

Aims to market enhanced versions of existing medicines

Novartis building

Novartis sets sights on eliminating leprosy

Throws weight behind meeting WHO's 2020 eradication goal

Novartis building

Scientists finds new drug target for malaria

Novartis and academics identify new class of medicines to treat all stages of infection

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

Biogen Idec building

Biogen Idec wins EU battle on Tecfidera exclusivity

Oral MS drug gains New Active Substance status

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

- PMLiVE

Teva withdraws US filing for cancer biologic

FDA requests more data for balugrastim

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links